D M Asmuth1, K Abel, M D George, S Dandekar, R B Pollard, C J Miller. 1. Division of Infectious Diseases, Department of Internal Medicine, University of California-Davis Medical Center, 4150 V Street, Sacramento, CA 95817, USA. david.asmuth@ucdmc.ucdavis.edu
Abstract
BACKGROUND: In vitro and clinical observations in HIV-infected patients receiving interferon alpha therapy have shown a reduction in HIV loads. Limited investigations have explored the innate or adaptive immune responses of IFN-alpha on SIV replication in vivo. METHODS: Seven chronically infected rhesus macaques were given pegylated IFN-alpha 2a (n = four) or saline (n = three) injections once weekly for 14 weeks. Weekly peripheral blood samples were taken for safety parameters, viral load determinations, and measurements of innate and adaptive immune responses. RESULTS: Pharmacokinetic measurements demonstrated therapeutic peg-IFN-alpha levels for the initial period of therapy and IFN-alpha inducible antiviral molecules were increased sporadically in the PBMC mRNA of the treatment group. Despite the demonstrable effect of the IFN-alpha injections, the treatment had no effect on plasma viral RNA levels. CONCLUSIONS: This work demonstrates that while short term IFN-alpha therapy induces innate antiviral immunity, it does not dramatically enhance or suppress viral replication. However, studies in the SIV model to determine therapeutic potential of chronic IFN-alpha therapy for the treatment of HIV will require macaque specific cytokines.
BACKGROUND: In vitro and clinical observations in HIV-infectedpatients receiving interferon alpha therapy have shown a reduction in HIV loads. Limited investigations have explored the innate or adaptive immune responses of IFN-alpha on SIV replication in vivo. METHODS: Seven chronically infected rhesus macaques were given pegylated IFN-alpha 2a (n = four) or saline (n = three) injections once weekly for 14 weeks. Weekly peripheral blood samples were taken for safety parameters, viral load determinations, and measurements of innate and adaptive immune responses. RESULTS: Pharmacokinetic measurements demonstrated therapeutic peg-IFN-alpha levels for the initial period of therapy and IFN-alpha inducible antiviral molecules were increased sporadically in the PBMC mRNA of the treatment group. Despite the demonstrable effect of the IFN-alpha injections, the treatment had no effect on plasma viral RNA levels. CONCLUSIONS: This work demonstrates that while short term IFN-alpha therapy induces innate antiviral immunity, it does not dramatically enhance or suppress viral replication. However, studies in the SIV model to determine therapeutic potential of chronic IFN-alpha therapy for the treatment of HIV will require macaque specific cytokines.
Authors: P H Frissen; F de Wolf; P Reiss; P J Bakker; C H Veenhof; S A Danner; J Goudsmit; J M Lange Journal: J Infect Dis Date: 1997-09 Impact factor: 5.226
Authors: D W Haas; J Lavelle; J P Nadler; S B Greenberg; P Frame; N Mustafa; M St Clair; R McKinnis; L Dix; M Elkins; J Rooney Journal: AIDS Res Hum Retroviruses Date: 2000-02-10 Impact factor: 2.205
Authors: Netanya G Sandler; Steven E Bosinger; Jacob D Estes; Richard T R Zhu; Gregory K Tharp; Eli Boritz; Doron Levin; Sathi Wijeyesinghe; Krystelle Nganou Makamdop; Gregory Q del Prete; Brenna J Hill; J Katherina Timmer; Emma Reiss; Ganit Yarden; Samuel Darko; Eduardo Contijoch; John Paul Todd; Guido Silvestri; Martha Nason; Robert B Norgren; Brandon F Keele; Srinivas Rao; Jerome A Langer; Jeffrey D Lifson; Gideon Schreiber; Daniel C Douek Journal: Nature Date: 2014-07-09 Impact factor: 49.962
Authors: Sho Sugawara; Ramy El-Diwany; Laura K Cohen; Kimberly E Rousseau; Christopher Y K Williams; Rebecca T Veenhuis; Shruti H Mehta; Joel N Blankson; David L Thomas; Andrea L Cox; Ashwin Balagopal Journal: J Virol Date: 2021-03-03 Impact factor: 5.103
Authors: Shannon R Matzinger; Timothy D Carroll; Linda Fritts; Michael B McChesney; Christopher J Miller Journal: PLoS One Date: 2011-12-29 Impact factor: 3.240